Skip to main content
Erschienen in: Medical Oncology 1/2024

01.01.2024 | Original Paper

Isolation and characterization of a novel single-chain variable fragment (scFv) against Lymphocyte function-associated antigen-1 (LFA-1) using phage display method

verfasst von: Fatemeh Afsharnoori, Mehdi Forouzandeh Moghadam

Erschienen in: Medical Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Lymphocyte function-associated antigene-1 (LFA-1) is a well-described integrin found on lymphocytes and other leukocytes, which is known to be overexpressed in leukemias and lymphomas. This receptor plays a significant role in immune responses such as T-cell activation, leukocyte cell–cell interactions, and trafficking of leukocyte populations. Subsequently, binders of LFA-1 emerge as potential candidates for cancer and autoimmune therapy. This study used the phage display technique to construct and characterize a high-affinity single-chain fragment variable (scFv) antibody against LFA-1. After expression, purification, dialysis, and concentration of the recombinant LFA-1 protein, four female BALB/c mice were immunized, splenocyte’s mRNA was extracted, and cDNA was synthesized. A scFv library was constructed by linking the amplified VH/Vκ fragments through a 72-bp linker using SOEing PCR. Next, the scFv gene fragments were cloned into the pComb-3XSS phagemid vector; thus, the phage library was developed. The selection process involved three rounds of phage-bio-panning, polyclonal, and monoclonal phage ELISA. AF17 was chosen and characterized among the positive clones through SDS-PAGE, Western blotting, indirect ELISA, and in-silico analyses. The results of the study showed the successful construction of a high-affinity scFv library against LFA-1. The accuracy of the AF17 production and its ability to bind to the LFA-1 were confirmed through SDS-PAGE, Western blot, and ELISA. This study highlights the potential application of the high-affinity AF17 against LFA-1 for targeting T lymphocytes for therapeutic purposes.
Literatur
1.
Zurück zum Zitat Li D, Molldrem JJ, Ma Q. LFA-1 regulates CD8+ T cell activation via T cell receptor-mediated and LFA-1-mediated Erk1/2 signal pathways. J Biol Chem. 2009;284(31):21001–10.CrossRefPubMedPubMedCentral Li D, Molldrem JJ, Ma Q. LFA-1 regulates CD8+ T cell activation via T cell receptor-mediated and LFA-1-mediated Erk1/2 signal pathways. J Biol Chem. 2009;284(31):21001–10.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33(1):5–12.CrossRefPubMedPubMedCentral Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33(1):5–12.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kozani PS, Shabani S. Adverse events and side effects of chimeric antigen receptor (CAR) T cell therapy in patients with hematologic malignancies. Trends Med Sci. 2021;1(1):e116301. Kozani PS, Shabani S. Adverse events and side effects of chimeric antigen receptor (CAR) T cell therapy in patients with hematologic malignancies. Trends Med Sci. 2021;1(1):e116301.
5.
Zurück zum Zitat Phongpradist R, Chittasupho C, Okonogi S, Siahaan T, Anuchapreeda S, Ampasavate C, Berkland C. LFA-1 on leukemic cells as a target for therapy or drug delivery. Curr Pharm Des. 2010;16(21):2321–30.CrossRefPubMedCentral Phongpradist R, Chittasupho C, Okonogi S, Siahaan T, Anuchapreeda S, Ampasavate C, Berkland C. LFA-1 on leukemic cells as a target for therapy or drug delivery. Curr Pharm Des. 2010;16(21):2321–30.CrossRefPubMedCentral
6.
Zurück zum Zitat Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, Kirsch MI, Schütte M, Helmsing S, Meier D, Schirrmann T. A human scFv antibody generation pipeline for proteome research. J Biotechnol. 2011;152(4):159–70.CrossRefPubMed Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, Kirsch MI, Schütte M, Helmsing S, Meier D, Schirrmann T. A human scFv antibody generation pipeline for proteome research. J Biotechnol. 2011;152(4):159–70.CrossRefPubMed
7.
Zurück zum Zitat Kumar R, Parray HA, Shrivastava T, Sinha S, Luthra K. Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol. 2019;135:907–18.CrossRef Kumar R, Parray HA, Shrivastava T, Sinha S, Luthra K. Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol. 2019;135:907–18.CrossRef
8.
Zurück zum Zitat Kaboli PJ, Shabani S, Sharma S, Nasr MP, Yamaguchi H, Hung MC. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12(4):1671. Kaboli PJ, Shabani S, Sharma S, Nasr MP, Yamaguchi H, Hung MC. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12(4):1671.
9.
Zurück zum Zitat Nikolova G, Georgieva Y, Atanasova A, Radulova G, Kapogianni A, Tsacheva I. Autoinduction as means for optimization of the heterologous expression of recombinant single-chain Fv (scFv) antibodies. Mol Biotechnol. 2021;63(11):1049–56.CrossRef Nikolova G, Georgieva Y, Atanasova A, Radulova G, Kapogianni A, Tsacheva I. Autoinduction as means for optimization of the heterologous expression of recombinant single-chain Fv (scFv) antibodies. Mol Biotechnol. 2021;63(11):1049–56.CrossRef
10.
Zurück zum Zitat Accardi L, Di Bonito P. Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem. 2010;17(17):1730–55.CrossRefPubMed Accardi L, Di Bonito P. Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem. 2010;17(17):1730–55.CrossRefPubMed
11.
Zurück zum Zitat Kuhn P, Fühner V, Unkauf T, Moreira GM, Frenzel A, Miethe S, Hust M. Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. Proteom Clin Appl. 2016;10(9–10):922–48.CrossRef Kuhn P, Fühner V, Unkauf T, Moreira GM, Frenzel A, Miethe S, Hust M. Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. Proteom Clin Appl. 2016;10(9–10):922–48.CrossRef
12.
Zurück zum Zitat Jeong KJ, Jang SH, Velmurugan N. Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J. 2011;6(1):16–27.CrossRef Jeong KJ, Jang SH, Velmurugan N. Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J. 2011;6(1):16–27.CrossRef
13.
Zurück zum Zitat Miethe S, Meyer T, Wöhl-Bruhn S, Frenzel A, Schirrmann T, Dübel S, Hust M. Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEX™ bioreactor. J Biotechnol. 2013;163(2):105–11.CrossRef Miethe S, Meyer T, Wöhl-Bruhn S, Frenzel A, Schirrmann T, Dübel S, Hust M. Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEX™ bioreactor. J Biotechnol. 2013;163(2):105–11.CrossRef
14.
Zurück zum Zitat Shukra AM, Sridevi NV, Chandran D, Maithal K. Production of recombinant antibodies using bacteriophages. Eur J Microbiol Immunol. 2014;4(2):91–8.CrossRef Shukra AM, Sridevi NV, Chandran D, Maithal K. Production of recombinant antibodies using bacteriophages. Eur J Microbiol Immunol. 2014;4(2):91–8.CrossRef
15.
Zurück zum Zitat Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. J Immunol Res. 2012;2012. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. J Immunol Res. 2012;2012.
16.
Zurück zum Zitat Fath MK, Naderi M, Hamzavi H, Ganji M, Shabani S, Khalesi B, Pourzardosht N, Hashemi ZS, Khalili S. Molecular Mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients. J Trace Elem Med Biol. 2022;73:127044.CrossRefPubMedCentral Fath MK, Naderi M, Hamzavi H, Ganji M, Shabani S, Khalesi B, Pourzardosht N, Hashemi ZS, Khalili S. Molecular Mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients. J Trace Elem Med Biol. 2022;73:127044.CrossRefPubMedCentral
17.
Zurück zum Zitat André AS, Moutinho I, Dias JN, Aires-da-Silva F. In vivo Phage Display: a promising selection strategy for the improvement of antibody targeting and drug delivery properties. Front Microbiol. 2022;13:962124.CrossRefPubMedPubMedCentral André AS, Moutinho I, Dias JN, Aires-da-Silva F. In vivo Phage Display: a promising selection strategy for the improvement of antibody targeting and drug delivery properties. Front Microbiol. 2022;13:962124.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Shabani S, Moghadam MF, Gargari SL. Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method. Med Oncol. 2021;38(9):115.CrossRefPubMed Shabani S, Moghadam MF, Gargari SL. Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method. Med Oncol. 2021;38(9):115.CrossRefPubMed
19.
20.
Zurück zum Zitat Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A, Nickho H, Yousefi M, Majidi J. Phage display as a promising approach for vaccine development. J Biomed Sci. 2016;23:1–8.CrossRef Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A, Nickho H, Yousefi M, Majidi J. Phage display as a promising approach for vaccine development. J Biomed Sci. 2016;23:1–8.CrossRef
21.
Zurück zum Zitat Sioud M. Phage display libraries: from binders to targeted drug delivery and human therapeutics. Mol Biotechnol. 2019;61(4):286–303.CrossRefPubMed Sioud M. Phage display libraries: from binders to targeted drug delivery and human therapeutics. Mol Biotechnol. 2019;61(4):286–303.CrossRefPubMed
22.
23.
Zurück zum Zitat Hashemi A, Bigdeli R, Shahnazari M, Oruji F, Fattahi S, Panahnejad E, Ghadri A, Movahedi-Asl E, Mahdavi-Ourtakand M, Asgary V, Baghbani-Arani F. Evaluation of inflammasome activation in peripheral blood mononuclear cells of hemodialysis treated patients with glomerulonephritis. Iran J Pharm Res. 2021;20(3):609.PubMedPubMedCentral Hashemi A, Bigdeli R, Shahnazari M, Oruji F, Fattahi S, Panahnejad E, Ghadri A, Movahedi-Asl E, Mahdavi-Ourtakand M, Asgary V, Baghbani-Arani F. Evaluation of inflammasome activation in peripheral blood mononuclear cells of hemodialysis treated patients with glomerulonephritis. Iran J Pharm Res. 2021;20(3):609.PubMedPubMedCentral
24.
Zurück zum Zitat Oruji F, Baghbani Arani F, Mahdavi OM. Evaluation of the gene expression of IL-1β and Casp-1 related to inflammation process in glomerulonephritis patients. J Anim Environ. 2018;10(3):477–82. Oruji F, Baghbani Arani F, Mahdavi OM. Evaluation of the gene expression of IL-1β and Casp-1 related to inflammation process in glomerulonephritis patients. J Anim Environ. 2018;10(3):477–82.
25.
Zurück zum Zitat Ohashi Y, Minegishi M, Tsuchiya S, Konno T. Three monoclonal antibodies against human LFA-1 α and β chains with different biological activities. Tohoku J Exp Med. 1992;168(4):599–610.CrossRef Ohashi Y, Minegishi M, Tsuchiya S, Konno T. Three monoclonal antibodies against human LFA-1 α and β chains with different biological activities. Tohoku J Exp Med. 1992;168(4):599–610.CrossRef
26.
Zurück zum Zitat Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003;49(2):98–104.CrossRef Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003;49(2):98–104.CrossRef
27.
Zurück zum Zitat Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52.CrossRef Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52.CrossRef
28.
Zurück zum Zitat Gaughan CL. The present state of the art in expression, production and characterization of monoclonal antibodies. Mol Divers. 2016;20(1):255–70.CrossRefPubMed Gaughan CL. The present state of the art in expression, production and characterization of monoclonal antibodies. Mol Divers. 2016;20(1):255–70.CrossRefPubMed
29.
Zurück zum Zitat Mehralizadeh H, Nazari A, Oruji F, Roostaie M, Hosseininozari G, Yazdani O, Esbati R, Roudini K. Cytokine sustained delivery for cancer therapy; special focus on stem cell-and biomaterial-based delivery methods. Pathol Res Pract. 2023;9:154528.CrossRef Mehralizadeh H, Nazari A, Oruji F, Roostaie M, Hosseininozari G, Yazdani O, Esbati R, Roudini K. Cytokine sustained delivery for cancer therapy; special focus on stem cell-and biomaterial-based delivery methods. Pathol Res Pract. 2023;9:154528.CrossRef
30.
Zurück zum Zitat Reader RH, Workman RG, Maddison BC, Gough KC. Advances in the production and batch reformatting of phage antibody libraries. Mol Biotechnol. 2019;61:801–15.CrossRefPubMedPubMedCentral Reader RH, Workman RG, Maddison BC, Gough KC. Advances in the production and batch reformatting of phage antibody libraries. Mol Biotechnol. 2019;61:801–15.CrossRefPubMedPubMedCentral
31.
32.
Zurück zum Zitat Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. In: MAbs 2022 (Vol. 14, No. 1, p. 2014296). Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. In: MAbs 2022 (Vol. 14, No. 1, p. 2014296).
33.
Zurück zum Zitat Anand T, Virmani N, Bera BC, Vaid RK, Vashisth M, Bardajatya P, Kumar A, Tripathi BN. Phage display technique as a tool for diagnosis and antibody selection for coronaviruses. Curr Microbiol. 2021;78(4):1124–34.CrossRefPubMedCentral Anand T, Virmani N, Bera BC, Vaid RK, Vashisth M, Bardajatya P, Kumar A, Tripathi BN. Phage display technique as a tool for diagnosis and antibody selection for coronaviruses. Curr Microbiol. 2021;78(4):1124–34.CrossRefPubMedCentral
34.
Zurück zum Zitat Dong Y, Meng F, Wang Z, Yu T, Chen A, Xu S, Wang J, Yin M, Tang L, Hu C, Wang H. Construction and application of a human scFv phage display library based on Cre-LoxP recombination for anti-PCSK9 antibody selection. Int J Mol Med. 2021;47(2):708–18.CrossRef Dong Y, Meng F, Wang Z, Yu T, Chen A, Xu S, Wang J, Yin M, Tang L, Hu C, Wang H. Construction and application of a human scFv phage display library based on Cre-LoxP recombination for anti-PCSK9 antibody selection. Int J Mol Med. 2021;47(2):708–18.CrossRef
35.
Zurück zum Zitat Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindqvist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci. 1998;95(11):6157–62.CrossRefPubMedPubMedCentral Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindqvist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci. 1998;95(11):6157–62.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, Muyldermans S, Hol WG, Kobilka BK, Steyaert J. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9(3):674–93.CrossRefPubMedPubMedCentral Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, Muyldermans S, Hol WG, Kobilka BK, Steyaert J. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9(3):674–93.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987;100(1–2):173–9.CrossRefPubMed Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987;100(1–2):173–9.CrossRefPubMed
Metadaten
Titel
Isolation and characterization of a novel single-chain variable fragment (scFv) against Lymphocyte function-associated antigen-1 (LFA-1) using phage display method
verfasst von
Fatemeh Afsharnoori
Mehdi Forouzandeh Moghadam
Publikationsdatum
01.01.2024
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2024
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-023-02242-z

Weitere Artikel der Ausgabe 1/2024

Medical Oncology 1/2024 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.